Compositions and methods for preventing and treating radiation-induced bystander effects caused by radiation or radiotherapy

Patent metadata

Field	Value
Publication number	US-12447142-B2
Application number	US-202217852475-A
Country	US
Kind code	B2
Filing date	Jun 29, 2022
Priority date	Jul 17, 2017
Publication date	Oct 21, 2025
Grant date	Oct 21, 2025

Abstract

The invention provides novel compositions and methods for the treatment of Radiation-Induced Bystander Effects (RIBE), resulting from radiation exposure. In one preferred embodiment the inventions includes novel therapeutic agents, including but not limited to quercetin and quercetin analogs, as well as E64, CA074, CA074Me, that interfere with the activity of Cathepsin B.

First claim

What is claimed is:

1. A method for ameliorating radiation-induced bystander effects (RIBE) in non-irradiated cells of a subject caused by exposure to radiation, comprising administering to the subject a therapeutically effective amount of an agent that inhibits the protease activity of protein Cathepsin B (CTSB), wherein the agent is selected from: quercetin, isoquercetin, E64, CA074 and CA074Me.

2. A method for ameliorating radiation-induced bystander effects (RIBE) in a subject caused by exposure to radiation as described in claim 1 , wherein said agent is administered to the subject in a pharmaceutical composition.

3. A method for ameliorating radiation-induced bystander effects (RIBE) in a subject caused by exposure to radiation as described in claim 1 , and further comprising the step of providing an anti-cancer therapy.

4. A method for ameliorating radiation-induced bystander effects in a subject (RIBE) caused by exposure to radiation as described in claim 3 , wherein the anti-cancer therapy is selected from the group consisting of: surgery, chemotherapy, and immunotherapy.

5. A method for ameliorating radiation-induced bystander effects (RIBE) in a subject caused by exposure to radiation as described in claim 1 , wherein the agent is administered to the subject:
prior to the administration of the radiotherapy; or
along with the administration of the radiotherapy; or
after the administration of the radiotherapy.

6. A method for ameliorating radiation-induced bystander effects (RIBE) in a subject caused by exposure to radiation as described in claim 1 , wherein the agent alters cell death, cell proliferation, reduces DNA damage, or increases DNA repair in the subject.

7. A method for ameliorating radiation-induced bystander effects (RIBE) in a subject caused by exposure to radiation as described in claim 1 , wherein the therapeutically effective amount of an agent produces one of the following effects in a subject:
increases the effectiveness of radiotherapy in a cancer subject in a subject;
increases the effectiveness of chemotherapy in a cancer subject in a subject;
reduces resistance of cancer cells to radiotherapy or chemotherapy in a subject; and
increases the subject's tolerance to radiotherapy.

Assignees

• Univ Colorado Regents

Inventors

• Xue Ding
• Peng Yu
• Zhang Man
• Zheng Lingjun
• Liang Qian
• Li Hanzeng
• Yu Jau-Song
• Chen Jeng-Ting

Classifications

• G01N33/575

  for cancer · CPC title

• A61K31/7048

  having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin} · CPC title

• A61K31/4025

  not condensed and containing further heterocyclic rings, e.g. cromakalim · CPC title

• A61K31/353 Primary

  3,4-Dihydrobenzopyrans, e.g. chroman, catechin · CPC title

• A61K31/336

  having three-membered rings, e.g. oxirane, fumagillin · CPC title